USP1 and Miyoshi myopathy: SJB3-019A is an inhibitor that selectively blocks USP1 enzymatic activity, and treatment of multiple myeloma (MM) cells with SJB3-019A triggers apoptosis and downregulates MM stem cell renewal [85].